AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05826574
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules.
Trial: NCT05826574
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsules.
Trial: NCT05181215
Drug: Diroximel Fumarate 462 mg
RxNorm normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 x 231 mg capsules, delayed-release
Trial: NCT00002123
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002123
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05008341
Drug: Solriamfetol 150 mg Oral Tablet
RxNorm normalized name: Solriamfetol 150 MG Oral Tablet
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-dose 150 mg tablet orally administered.
Trial: NCT00002179
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002179
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002179
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05041036
Drug: Nirogacestat (Gamma Secretase Inhibitor)
RxNorm normalized name: nirogacestat
DrugBank: Nirogacestat (DB12005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive nirogacestat tablets to be taken orally.
Trial: NCT05653323
Drug: VX-993
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT04602377
Drug: Pembrolizumab 25 MG/ML [Keytruda]
RxNorm normalized name: pembrolizumab 25 MG/ML [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression.
Trial: NCT05690100
Drug: Gingi gel
RxNorm normalized name: Gingi Med
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory Gel which has a beneficial role on wound healing
Trial: NCT04910347
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs.
Trial: NCT05236543
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
Trial: NCT04949399
Drug: OnabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection
Trial: NCT06613750
Drug: Sitagliptin and Gliclazide
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks
Trial: NCT06613750
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks
Trial: NCT06614621
Drug: Adebrelimab +Etoposide+Platinum-based drugs
RxNorm normalized name: platinum
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adebrelimab：20mg/kg或1200mg ivgtt ，d1 ，Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs：75mg/m2， ivgtt， d1,d2,d3,Q3W
Trial: NCT06361940
Drug: Aromatase inhibitors or tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
Trial: NCT06613997
Drug: Albendazole 400mg
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 400mg per days for 21 consecutive days
Trial: NCT06617455
Drug: Fezolinetant
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05732389
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
Trial: NCT05732389
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
Trial: NCT06614231
Drug: Tislelizumab Combined With Chemotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy
Trial: NCT05464615
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
Trial: NCT05712278
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection , by IV injection
Trial: NCT05712278
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for injection, by IV injection
Trial: NCT06696482
Drug: Escitalopram 10mg
RxNorm normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
Trial: NCT06712173
Drug: linperlisib and SHR2554
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.
Trial: NCT06711471
Drug: trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).
Trial: NCT06713798
Drug: Atezolizumab 1200 mg IV
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atezolizumab (intravenous 1200mg Q3W)
Trial: NCT06713798
Drug: Tiragolumab 600 mg IV
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab (intravenous 600mg Q3W)
Trial: NCT06711146
Drug: Metabolically Armed CD19 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion
Trial: NCT06398626
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As provided in real world practice
Trial: NCT04604782
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
Trial: NCT05274789
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
Trial: NCT05373901
Drug: Dinutuximab Beta
RxNorm normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days
Trial: NCT05373901
Drug: 13-cis-Retinoic Acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
Trial: NCT05597098
Drug: Cantharidin
RxNorm normalized name: cantharidin
DrugBank: Cantharidin (DB12328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Trial: NCT06629129
Drug: Latanoprost (0.005%)
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT
Trial: NCT05032235
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Renal Function:A single oral dose of Fluzoparib will be administered.
Trial: NCT05032235
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
Trial: NCT05032235
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
Trial: NCT05599243
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
Trial: NCT05222607
Drug: IncobotulinumtoxinA
RxNorm normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: IncobotulinumtoxinA injections for aesthetic indications.
Trial: NCT04742218
Drug: K-877
RxNorm normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 Tablet
Trial: NCT05718297
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them.
Trial: NCT05718297
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
Trial: NCT06108492
Drug: SHR-2005
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy.
Trial: NCT05165069
Drug: Mecobalamin 5 MG Disintegrating Oral Tablet
RxNorm normalized name: mecobalamin 5 MG Disintegrating Oral Tablet
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
Trial: NCT04554771
Drug: Tocilizumab 20 Mg/mL Intravenous Solution
RxNorm normalized name: tocilizumab 20 mg/mL intravenous solution
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
Trial: NCT04554771
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
Trial: NCT04554771
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
Trial: NCT06474806
Drug: 64Cu-DOTA-AE105
RxNorm normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.
Trial: NCT06378879
Drug: Propofol 100 MG in 10 ML Injection
RxNorm normalized name: propofol 100 MG in 10 ML Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events
Trial: NCT05823987
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a PD-1 immune check inhibitor
Trial: NCT05823987
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsules
Trial: NCT04656470
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
Trial: NCT05051163
Drug: Ceftriaxone Sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days of once daily dosing
Trial: NCT05051163
Drug: Ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days of 6 hourly dosing
Trial: NCT06099821
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
Trial: NCT06099821
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
Trial: NCT06183073
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine 1μg/ kg.
Trial: NCT06183073
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% in a dose of (0.5 ml / kg
Trial: NCT06099821
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
Trial: NCT06260553
Drug: tislelizumab and metronomic oral vinorelbine
RxNorm normalized name: Tislelizumab
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
Trial: NCT05856981
Drug: ADU-1805
RxNorm normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-SIRPα monoclonal antibody
Trial: NCT05856981
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Keytruda
Trial: NCT05011513
Drug: PF-07321332
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07321332 (tablet)
Trial: NCT05011513
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir (capsule)
Trial: NCT03634189
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
Trial: NCT05536284
Drug: Bisoprolol Fumarate Tablets
RxNorm normalized name: Bisoprolol Fumarate Tablets
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antihypertensive drug used for acute coronary syndrome patients
Trial: NCT05099835
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
Trial: NCT05494437
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CB1 receptor
Trial: NCT05494437
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GABAergic modulator
Trial: NCT06518837
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
Trial: NCT06370013
Drug: Tinengotinib
RxNorm normalized name: Tinengotinib
DrugBank: Tinengotinib (DB17384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.
Trial: NCT05553041
Drug: 18F-Fluciclovine PET-MRI
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
Trial: NCT04338763
Drug: RP72
RxNorm normalized name: CXC chemokine receptor types 1 and 2 inhibitor RP72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
Trial: NCT04338763
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.